Rosetta Genomics Wins Credentialing Deal with Prime Health Services for miRview mets2

Rosetta Genomics Ltd.

, a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred Provider Organization (PPO), for the inclusion of Rosetta Genomics' miRview^® mets^2 test in Prime Health's covered products and services. The agreement with Prime Health is the first credentialing agreement executed between Rosetta Genomics and a U.S. PPO, and increases the number of covered lives for which its miRview^® mets^2 test could be adjudicated as "in-network" to more than 6.5 million.